Alternate Title
Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outcomes
Outline
Trial Contact Information
Registry Information

Alternate Title

Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Closed	18 and over	NCI	DFCI-03083 NCT00083031

Special Category: SPORE trial

Objectives

Primary

1. Compare the overall response rate in women with metastatic breast cancer treated with metronomic low-dose cyclophosphamide and methotrexate with or without bevacizumab.

Secondary

1. Compare the progression-free survival of patients treated with these regimens.
2. Compare the toxicity of these regimens in these patients.
3. Correlate markers of angiogenesis, including vascular endothelial growth factor and circulating endothelial cells, at baseline and during treatment, with response in patients treated with these regimens.

Entry Criteria

Disease Characteristics:

• Histologically or cytologically confirmed invasive breast cancer
  • Metastatic (stage IV) disease confirmed by histology or cytology, physical exam, or radiologic study



• Measurable disease
  • At least one unidimensionally measurable lesion at least 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
  • Measurable lesions in a previously irradiated field must have progressed after radiotherapy



• HER2-positive patients must have received prior trastuzumab (Herceptin^®) for advanced disease or in the adjuvant setting



• No evidence of brain metastases by brain CT scan or MRI



• Hormone receptor status:
  • Not specified

Prior/Concurrent Therapy:

Biologic therapy

• See Disease Characteristics
• No prior experimental angiogenesis inhibitors
• No concurrent filgrastim (G-CSF)
• Concurrent epoetin alfa growth factor support allowed

Chemotherapy

• Prior adjuvant chemotherapy for early-stage breast cancer allowed, including cyclophosphamide-based chemotherapy
• No more than 1 prior chemotherapy regimen for metastatic breast cancer
• No prior oral cyclophosphamide- or methotrexate-based therapy for metastatic disease

Endocrine therapy

• Prior hormonal therapy in the adjuvant or metastatic setting or for early-stage breast cancer allowed
• No concurrent hormonal therapy, including luteinizing hormone-releasing hormone agonists

Radiotherapy

• See Disease Characteristics
• Prior radiotherapy in the metastatic or early-stage setting allowed
• Concurrent radiotherapy allowed

Surgery

• More than 28 days since prior surgery except for venous access device or diagnostic study

Other

• Recovered from prior therapy
• No concurrent anticoagulation or chronic aspirin therapy (> 325 mg/day)
  • Concurrent low-dose anticoagulation or thrombolytic agents for venous access patency allowed
• No other concurrent investigational or experimental therapy
• No other concurrent anticancer agents or therapies
• Concurrent bisphosphonates allowed provided skeletal sites are not the primary sites used in assessing response
  • If skeletal sites are being followed for measurable response, bisphosphonates must be initiated at least 4 weeks before study entry

Patient Characteristics:

Age

• 18 and over

Sex

• Female

Menopausal status

• Not specified

Performance status

• ECOG 0-1

  OR

• Karnofsky 70-100%

Life expectancy

• More than 6 months

Hematopoietic

• Absolute neutrophil count ≥ 1,000/mm³
• Platelet count ≥ 100,000/mm³
• No bleeding diatheses (including hemoptysis)

Hepatic

• AST and ALT ≤ 4.0 times upper limit of normal (ULN)
• Bilirubin ≤ 2 times ULN

Renal

• Creatinine ≤ 2.0 mg/dL
• Urinary protein < 500 mg/24-hour-urine collection

  OR

• Protein urinalysis < 1+

Cardiovascular

• LVEF ≥ 50% by echocardiogram or nuclear medicine gated study
• No poorly controlled hypertension
• No prior blood clots
• No symptomatic congestive heart failure
• No unstable angina pectoris
• No cardiac arrhythmia

Other

• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of grade 3 or 4 allergic reaction to compounds of similar chemical or biological composition to cyclophosphamide or methotrexate
• No concurrent uncontrolled illness
• No active or ongoing infection
• No psychiatric illness or social situation that would preclude study compliance

Expected Enrollment

A total of 36-66 patients (18-33 per treatment arm) will be accrued for this study within 7-12 months.

Outcomes

Clinical response rate (complete and partial) as measured by RECIST criteria

Progression-free survival

Outline

This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

• Arm I: Patients receive low-dose oral cyclophosphamide once daily on days 1-28, low-dose oral methotrexate twice daily on days 1, 2, 8, 9, 15, 16, 22 and 23, and bevacizumab IV over 30-90 minutes on days 1 and 15.



• Arm II: Patients receive cyclophosphamide and methotrexate as in arm I.

In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients in arm II who have progressive disease have the option of discontinuing treatment or crossing over to arm I.

Trial Contact Information

Trial Lead Organizations

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Harold J. Burstein, MD, PhD, Principal investigator		Ph: 617-632-3800; 866-790-4500 Email: hburstein@partners.org

Registry Information
Official Title		Metronomic Chemotherapy in Combination with Bevacizumab for Advanced Breast Cancer
Trial Start Date		2002-11-30
Registered in ClinicalTrials.gov		NCT00083031
Date Submitted to PDQ		2003-03-15
Information Last Verified		2005-09-06
NCI Grant/Contract Number		P30-CA06516, P50-CA89393

Back to Top